Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis
- PMID: 25641616
- DOI: 10.1002/ajh.23942
Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis
Comment on
-
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Am J Hematol. 2014 Oct;89(10):947-53. doi: 10.1002/ajh.23788. Epub 2014 Jul 21. Am J Hematol. 2014. PMID: 24944159 Free PMC article. Clinical Trial.
-
Systemic mastocytosis in a patient with Cowden syndrome.Am J Hematol. 2014 Dec;89(12):1154. doi: 10.1002/ajh.23815. Epub 2014 Aug 27. Am J Hematol. 2014. PMID: 25059215 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous